1Cooper BC, Sood AK, Davis CD, et al. Preoperative CA125 levels : an independent prognostic factor for epithelial ovarian cancer[J]. Obstet Gynecol, 2002, 100(1) :59-64.
2Rossi AC,Di Vagno G,Cormio G,et al. A retrospective study of preoperative CA125 levels in 82 patients with ovarian cancer[J].Arch Gynecol Obstet, 2004, 269 (4) :263-265.
3Paulsen T, Marth C, Kaern J, et al. Effects of paclitaxel on CA125 serum levels in ovarian cancer patients [ J ]. Gynecol Oncol, 2000, 76(3) :326-330.
4Nyvang GB, Mogensen O, Bichel P, et al. Combined prognostic importance of CA125, histopathologic grade and DNA index in advanced ovarian cancer[J]. Eur J Gynaecol Oncol, 2000, 21(6) :569-572.
5Rustin GJ, Marples M,Nelstrop AE, et al. Use of CA125 to define progression of ovarian cancer in patients with persistently elevated levels [ J ]. J Clin Oncol, 2001,19 ( 20 ) :4054-4057.
6Wilder JL, Pavlik E, Stranghn JM, et al. Clinical implications of a rising serum CA125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation[J]. Gynecol Oncol, 2003, 89(2):233-235.
7Gadducci A, Ferdeghini M, Castellani C, et al. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer [ J ]. Gynecol Oncol, 1998, 70 ( 1 ) :111-114.
8Stuart GC, Dawson LM. Update of granulosa cell tumours of the ovary[J]. Curr Opin Obstet Gynecol, 2003,15 ( 1 ) :33-37.
9Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer[ J ]. Lancet, 2002,359 ( 9306 ) :572-577.
10Pras E, Willemse PH, Canrinus AA, et al. Serum squamous cell carcinoma antigen and CYFRA21-1 in cervical cancer treatment[J]. Int J Radiat Oncol Biol Phys, 2002,52( 1 ) :23-32.
